Hyperthermic Intra-peritoneal Chemotherapy (HIPEC) in Ovarian Cancer Recurrence

Inclusion Criteria:

* Age over 18 and under 70 years
* Patients affected by a first recurrence of ovarian cancer with measurable lesions or not, but evaluable (upwards of Ca125 for 2 consecutive assessments).
* ECOG-performance status ≤ 2
* Ovarian cancer limited to the abdominal cavity with or without extraperitoneal spread considered resectable at intraoperative evaluation
* Evidence of tumor recurrence diagnosed after 6 months from primary treatment
* Previous-based chemotherapy of carboplatin and taxanes
* Positive Peritoneal Washing in the presence of other abdominal disease surgically resectable
* Adequate respiratory, hepatic, cardiac, kidney and bone marrow function (absolute neutrophil count \> 1500/mm3, platelets \> 150,000/μl, creatinine clearance \> 60 mL/min according to Cockroft formula)
* Patient-compliant and psychologically able to follow the trial procedures

Exclusion Criteria:

* Non-epithelial ovarian cancer or borderline ovarian tumor
* Pregnancy or breastfeeding
* Patients affected by major depressive disorder even in treatment or minor mood disorders
* Patients with severe impairment of respiratory, hepatic or renal function
* Patients with cardiac, neurological or metabolic uncontrolled pharmacologically disease
* Patients with active infection or other neoplastic disease in progress
* Patients with bowel obstruction
* Inadequate bone marrow, liver, kidney function
* No clear-peritoneal disease at surgical exploration
* Patients with ascites \> 500 ml (the TAC)
* Patients on maintenance therapy with Antiangiogenic drugs
* Patients with secondary or tertiary recurrence, or already submitted to HIPEC
* Patients who have already made the second or third line chemotherapy.